Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) comes with a heavy quality-of-life burden that doesn't ...

GSK plc announced the marketing authorisation of Exdensur (depemokimab) by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). In the UK, Exdensur is now approved in two indications: ...

State-level social welfare policies may address disparities in arthritis-related joint pain prevalence and education for ...

SereNeuro Therapeutics revealed promising results for SN101, a first-in-class iPSC-derived therapy designed to treat chronic osteoarthritis pain while protecting joint tissue. Instead of blocking pain ...

“Sustained exposure of elevated levels of lead poses increased potential toxicological risks to consumers to include ...

Pain represents the cardinal symptom of osteoarthritis, yet its intensity, quality, and impact vary dramatically among ...

A new stem cell–based therapy challenges traditional pain treatment by using pain-sensing neurons to reduce inflammation and protect joints. Newly released preclinical data describes an unconventional ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung ...

Parsonage-Turner syndrome (neuralgic amyotrophy) is a possibility, but there are other neurological causes of shoulder pain.

After two decades of surgeries, prescriptions, and debilitating symptoms, this mom discovered a treatment that significantly ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo Dupix ...

Rutgers Health experts have expanded treatment options for knee osteoarthritis, a condition caused by the gradual breakdown ...